

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM550829

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
PERCEPTIVE CREDIT OPPORTUNITIES FUND, LP		11/25/2019	Limited Partnership: DELAWARE
RECEIVING PARTY DATA			
Name:	KADMON CORPORATION, LLC		
Street Address:	450 East 29th Street		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10016		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 5			
Property Type	Number	Word Mark	
Registration Number:	2952736	RIBASPHERE	
Registration Number:	2887092	RIBASPHERE	
Registration Number:	3248539	RIBAPAK	
Registration Number:	4296020	KADMON	
Registration Number:	4296019	KADMON	
CORRESPONDENCE DATA			
Fax Number:	2124687900		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	212-336-4240		
Email:	hcheng@mofo.com		
Correspondent Name:	John Tawadrous		
Address Line 1:	250 West 55th Street		
Address Line 2:	Morrison & Foerster LLP		
Address Line 4:	New York, NEW YORK 10019		
ATTORNEY DOCKET NUMBER:	72295-8		
NAME OF SUBMITTER:	John Tawadrous		
SIGNATURE:	/John Tawadrous/		
DATE SIGNED:	11/25/2019		

CH \$140.00 2952736

Total Attachments: 11

source=Kadmon Corporation Security Agreement Termination#page1.tif
source=Kadmon Corporation Security Agreement Termination#page2.tif
source=Kadmon Corporation Security Agreement Termination#page3.tif
source=Kadmon Corporation Security Agreement Termination#page4.tif
source=Kadmon Corporation Security Agreement Termination#page5.tif
source=Kadmon Corporation Security Agreement Termination#page6.tif
source=Kadmon Corporation Security Agreement Termination#page7.tif
source=Kadmon Corporation Security Agreement Termination#page8.tif
source=Kadmon Corporation Security Agreement Termination#page9.tif
source=Kadmon Corporation Security Agreement Termination#page10.tif
source=Kadmon Corporation Security Agreement Termination#page11.tif

TERMINATION OF PATENT AND TRADEMARK SECURITY AGREEMENT

This Termination of Patent and Trademark Security Agreement (this “Termination”), dated as of November 25, 2019, is executed by PERCEPTIVE CREDIT OPPORTUNITIES FUND, LP (“Secured Party”), 51 Astor Place, 10th Floor, New York, NY 10003, in favor of KADMON CORPORATION, LLC, a Delaware limited liability company (the “Company”), 450 East 29th Street, New York, NY 10016.

RECITALS

WHEREAS, Company, certain Lenders and Secured Party, as the Collateral Representative, entered in a certain Credit Agreement, dated as of August 28, 2015 (the “Credit Agreement”); and

WHEREAS, in connection with the Credit Agreement, Company and Secured Party entered into a certain Patent and Trademark Security Agreement dated as of August 28, 2015 (the “Security Agreement”); and

WHEREAS, pursuant to the Security Agreement, Company granted to Secured Party a security interest in certain “Collateral” including certain patents and trademarks; and

WHEREAS, the Credit Agreement and the Security Agreement have been terminated.

NOW, THEREFORE, Secured Party agrees as follows:

1. Secured Party is executing and delivering this Termination as further evidence of the termination of the Security Agreement.
2. Secured Party claims no right, title or interest whatsoever in or to any of the “Collateral” described in the Security Agreement, and, accordingly, Secured Party expressly terminates its security interest in the patents and trademarks listed on Exhibit A hereto, which security interest was evidenced by the recordation of the Security Agreement with the United States Patent and Trademark Office on August 31, 2015, in Reel/Frame 5613/0325 and 036515/0084.

[Signature Page Follow]

IN WITNESS WHEREOF, this Termination is executed as of the first date written above.

PERCEPTIVE CREDIT OPPORTUNITIES
FUND, LP, as the Collateral Representative

By: PERCEPTIVE CREDIT
OPPORTUNITIES GP, LLC, its general
partner

By: 
Name: Sandeep Dixit
Title: Chief Credit Officer


By: 
Name: Sam Chawla
Title: Portfolio Manager

Exhibit A

to Termination of Patent and Trademark Security Agreement

KADMON CORPORATION, LLC

PATENTS AND PATENT APPLICATIONS

Matter	Country	Application No	Title	Status
473WO1	P.C.T.	PCT/US14/59572	RHO KINASE INHIBITORS (KL148 SERIES)	PENDING
474WO1	P.C.T.	PCT/US15/11657	IMMUNOMODULATORY AGENTS	PENDING
486P1	United States	62/185223	GLUCOSE UPTAKE INHIBITORS	PENDING
487P1	United States	62/185231	TREATMENT OF INFECTIOUS DISEASES WITH GLUCOSE UPTAKE INHIBITORS	PENDING
470US1	US [PCT]	14/431936	RHO KINASE INHIBITORS	PENDING
472US1	US [PCT]	14/431954	HUMAN ANTI-VEGFR-2/KDR ANTIBODIES	PENDING
472WO1	P.C.T.	PCT/US13/63754	HUMAN ANTI-VEGFR-2/KDR ANTIBODIES	PENDING
471US1	US [PCT]	14/431948	TREATMENT OF OCULAR DISORDERS	PENDING
475WO1	P.C.T.	PCT/US15/19658	TREATMENT OF BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS	PENDING
476WO1	P.C.T.	PCT/US15/25176	TREATMENT OF GVHD	PENDING
477P1	United States	62/061097	HUMAN ANTI-VEGFR-2/KDR ANTIBODIES	PENDING

467US2	United States	14/801335	METHODS FOR TREATMENT OF BREAST CANCER NONRESPONSIVE TO TRASTUZUMAB	PENDING
485P1	United States	62/113132	ANTI-PD1 ANTIBODIES	PENDING
462P1	United States	62/111522	STABLE TRIENTINE FORMULATIONS	PENDING

A. Kadmon Corporation, LLC has acquired exclusive rights in and to certain Patents and patent applications related to the compound XL647 pursuant to an Amended and Restated License Agreement, dated as of September 6, 2011, between Kadmon Corporation, LLC and Symphony Evolution, Inc. Such Patents and patent applications include:

Country	Title	Status	Application No.	Patent No.
USA	Receptor-Type Kinase Modulators and Methods of Use	Granted	10/522004	7576074
USA	Receptor-Type Kinase Modulators and Methods of Use	Granted	12/455867	8658654
USA	Receptor-Type Kinase Modulators and Methods of Use	Pending	14/060123	

Country	Title	Status	Application No.	Patent No.
USA	Use Of A Receptor-Type Kinase Modulator For Treating Polycystic Kidney Disease	Pending	13/818844	

B. Kadmon Corporation, LLC has acquired exclusive rights in and to certain Patents and patent applications related to the botanical compound PHY906 pursuant to a License Agreement, dated as of February 4, 2011, between Kadmon Corporation, LLC and Yale University. Such Patents and patent applications include:

Matter	Country Desc	Application No	Grant No	Title	Status Desc
462US2	US [PCT]	10/220876	7025993	HERBAL COMPOSITION PHY-906 AND ITD USE IN CHEMOTHERAPY	GRANTED
463US1	United States	11/100433	7534455	HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPY	GRANTED
465US1	US [PCT]	12/997513	8871279 B2	USE OF THE COMBINATION OF PHY906 AND A TYROSINE KINASE INHIBITOR AS A CANCER TREATMENT REGIMEN	GRANTED
466US2	United States	14/605180		USE OF PHY906 AS TREATMENT FOR INFLAMMATORT BOWEL DISEASE AND/OR IRRITABLE BOWEL SYNDROME	PENDING
464US3	United States	14/581610		HERBAL-COMPOSITION PHY906 AND ITS	PENDING

			USE IN CHEMOTHERAPY	
464US1	US [PCT]	12/527302	8309141 B2	GRANTED
			HERBAL-COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPY	

C. Kadmon Corporation, LLC has acquired exclusive rights in and to certain Patents and patent applications pursuant to that certain Exclusive License Agreement, dated as of December 8, 2010, between Kadmon Corporation, LLC and Princeton University. Such Patents and patent applications include:

Matter	Country Desc	Application No	Grant No	Title	Status Desc
46102	US [PCT]	13/579967		INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS	ALLOWED
464US1	US [PCT]	13/982331		INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS	PENDING
46276	P.C.T.	PCT/US10/43101		INHIBITORS OF CELL-CODED MTOR KINASE WITH ANTI-VIRAL ACTIVITY	PENDING
46202	US [PCT]	13/386547		INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS	PENDING
46003	United States	12/156517	8158677 B2	TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS	GRANTED
46004	United States	13/438616	9029413 B2	TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS	GRANTED
46005	United States	14/709756		TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS	PENDING

D. Kadmon Corporation, LLC has acquired exclusive rights in and to certain Patents and patent applications pursuant to that certain Sub-License Agreement, dated as of April 8, 2011, among NT Life Sciences, LLC, Kadmon Corporation, LLC, and Surface Logix, Inc. Such Patents and patent applications include:

Family	Country	Application No.	Grant No.	Title	Status
217US2	United States	13/715644	8916576 B2	PHARMACOKINETICALLY IMPROVED COMPOUNDS	GRANTED
217US3	United States	14/581746		PHARMACOKINETICALLY IMPROVED COMPOUNDS	PENDING
217US	US [PCT]	11/887218	8357693 B2	PHARMACOKINETICALLY IMPROVED COMPOUNDS	GRANTED
218US2	United States	13/708420	8853394	PHARMACOKINETICALLY IMPROVED COMPOUNDS	GRANTED
230US	US [PCT]	13/255879		RHO KINASE INHIBITORS	PENDING
Case	Status	App Number	Country Name	Pat Number	Title
69587/	Granted	11/407,500	USA	8980915	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND APO-B SECRETION
69587/CON	Pending	14/660,453	USA		INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND

APO-B
SECRETION


E. Kadmon Corporation, LLC has acquired exclusive rights in and to certain Patents and patent applications related to MMP-14 antibodies pursuant to that certain License Agreement, dated as of September 16, 2012, between Kadmon Corporation, LLC and Dyax Corp. Such Patents and patent applications include:


Docket No.	Country	Application No.	Patent No.	Status	Title
K2043-708710	US	11/648423	7745587	Granted	ANTIBODIES THAT BIND MMP-14
K2043-708720	US	12/776195	8106168	Granted	METALLOPROTEINASE BINDING PROTEINS
K2043-708721	US	13/335185	9051377	Granted	METHOD FOR TREATING BREAST CANCER USING ANTIBODY BINDING TO MMP-14
K2043-710210	US	12/337218	8183008	Granted	EVALUATING MMP EXPRESSION IN PATIENT STRATIFICATION AND OTHER THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR CANCER
K2043-710610	US	12/337140	8147836	Granted	COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS
K2043-710640	US	13/338622	8501181	Granted	COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS
K2043-7141US	US	14/353212		Pending	COMBINATION THERAPY COMPRISING AN MMP-14 BINDING PROTEIN

F. Kadmon Corporation, LLC has acquired exclusive rights in and to certain Patents and patent applications related to salirasinito pursuant to that certain Asset Purchase Agreement, dated as of December 16, 2011, between Kadmon Corporation, LLC and Concordia Pharmaceuticals, Inc. Such Patents and patent applications include:

Country	Appl. / Patent	Title	Status
United States	5,705,528 (RE39682)	FARNESYL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM	Granted
United States	6,462,086	NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS	Granted
United States	6,946,485	TREATMENT OF POST-ANGIOPLASTY RESTENOSIS AND ATHEROSCLEROSIS WITH RAS ANTAGONISTS	Granted
United States	8,232,253	TREATMENT OF LUNG CANCER	Granted
United States	8,338,481	ALKOXYALKYL S-PRENYLTHIOSALICYLATES FOR TREATMENT OF CANCER	Granted
United States	13/521,637	TREATMENT OF MULTIPLE SCLEROSIS	Filed
Canada	2577310	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Granted
United States	8,088,756	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Granted
United States	14/662420	METHODS AND COMPOSITIONS FOR ORAL DELIVERY OF FTS	Pending

TRADEMARKS AND TRADEMARK APPLICATIONS

Record	Mark/Serial/App./Reg. No.	Status/Key Dates	Goods/Services	Owner
US Federal	RIBASPHERE and Design 	Registered: May 17, 2005 Class 5 First Use: April 7, 2004 Filed: July 29, 2003	Class 5: Pharmaceutical preparations for use, through prescription, in the treatment of chronic hepatitis c	Kadmon Corporation, LLC
US Federal	RIBASPHERE SN:76-412404 RN:2,887,092	Registered: September 21, 2004 Class 5 First Use: April 7, 2004 Filed: May 24, 2002	Class 5: Pharmaceutical preparations for use, through prescription, in the treatment of chronic hepatitis c	Kadmon Corporation, LLC
US Federal	RIBAPAK SN:78-721241 RN:3,248,539	Registered: May 29, 2007 Class 5 First Use: September 29, 2006 Filed: September 27, 2005	Class 5: Pharmaceutical preparation for the treatment of hepatitis c	Kadmon Corporation, LLC

Record	Mark/Serial/App./Reg. No.	Status/Key Dates	Goods/Services	Owner
US Federal	KADMON and Design 	Registered February 26, 2013 Class 5 First Use: August 28, 2012 Filed: October 8, 2010	Class 5: Pharmaceuticals for use in the fields of oncology, immunology and viruses	Kadmon Corporation, LLC
US Federal	KADMON SN:85-148670 RN:4,296,020 SN:85-148651 RN:4,296,019	Registered February 26, 2013 Class 5 First Use: August 28, 2012 Filed: October 8, 2010	Class 5: Pharmaceuticals for use in the fields of oncology, immunology and viruses	Kadmon Corporation, LLC